Preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumors of glial origin – imply on diagnosis and early prognosis - a prospective clinical trial
Abstract
PET/CT
targeting
prostate-specific
membrane
antigen
(PSMA)
is
commonly
used
in
patients
with
prostate
cancer.
PSMA
has
been
found
other
solid
tumours,
including
primary
brain
tumours.
The
aim
of
this
study
was
to
evaluate
the
usefulness
[68Ga]Ga-PSMA-11
for
preoperative
diagnosis
and
2-year
prognosis.
We
prospectively
screened
suspected
glioma
tumour.
qualitative
quantitative
results
were
compared
histopathological
examination.
glioblastoma
(GBM)
diagnostic
data
or
between
high-grade
(HGG)
low-grade
(LGG)
gliomas.
Overall
(OS)
progression
free
survival
(PFS)
analysed.
Forty-four
met
inclusion
criteria.
Twenty
them
had
positive
twenty-four
negative
scans.
sensitivity,
specificity,
predictive
value,
value
HGG
71.4
(95%
confidence
interval
–
51.3–86.8),
100.0
(79.4–100.0),
(83.1–100.0),
66.7
(44.7–84.4),
respectively.
For
differentiation
GBM
vs
non-GBM
best
parameter
tumor-to-background
ratio,
area
under
receiver
operating
characteristic
curve
0.81
(0.66–0.96;
42.2)
CI;
cut-off).
Patients
scans
similar
PFS
OS
HGG.
accumulation
negatively
affected
diagnosed
GBM.
showed
optimistic
may
be
prognostic
a
factor.
Registration
at
www.clinicaltrials.gov
09/06/2023
number
NCT05896449
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 8, 2024
Language: Английский